Publications by authors named "W L Tew"
Objective: We sought to describe the association between genomic instability score (GIS) and progression-free survival (PFS) and overall survival (OS) in patients with newly diagnosed, non-BRCA1/2 ovarian cancer.
Methods: Homologous recombinant deficiency (HRD) status was based on a cutoff of ≥42 GIS; patients <42 were categorized with homologous recombination proficiency (HRP). We collected type and duration of maintenance therapy, among other variables, and built a multivariate model with landmark analysis at 6 months from baseline and applied it for time-dependent variables.
Purpose: Inhibition of the cyclin D-cyclin dependent kinase (CDK)4/6-INK4-retinoblastoma pathway can overcome acquired or de novo treatment resistance to endocrine monotherapy. Responses to endocrine monotherapy in advanced endometrial cancer (EC) are suboptimal, perhaps due to genomic alterations that promote estrogen receptor (ER)-independent cyclin D1-CDK4/6 activation. We hypothesized that addition of abemaciclib, a CDK4/6 kinase inhibitor, to antiestrogen therapy with fulvestrant will be an effective therapeutic strategy in patients with advanced or recurrent EC.
View Article and Find Full Text PDFArticle Synopsis
- Modern medicine often relies on targeting single compounds to treat diseases, which may be insufficient for complex, multifactorial illnesses.
- The study examines the combined effects of three compounds from the medicinal plant Orthosiphon stamineus—sinensetin, eupatorin, and TMF—finding that certain combinations can significantly enhance vasodilation beyond the effects of individual compounds.
- Results showed that specific combinations, particularly G2, G7, G27, and G28, led to high levels of vasodilatory efficacy, indicating the potential of botanical medicines for more effective treatment strategies.
Vascular resection and reconstruction in recurrent granulosa cell tumor.
Gynecol Oncol Rep
October 2024
Article Synopsis
- Oncovascular surgery is a specialized area in radical surgery for gynecologic cancers that involves teamwork across different medical fields, highlighted by a unique case of a patient with recurrent granulosa cell tumor.
- The patient, initially diagnosed in 1989, faced multiple recurrences and required extensive surgical intervention for a large tumor that invaded critical blood vessels, necessitating a complex surgical team collaboration.
- This case is significant as it's reportedly the first instance of oncovascular surgery targeting the aorta and inferior vena cava for this type of tumor, with the patient showing no evidence of disease 26 months post-operation.
Article Synopsis
- The study aimed to compare the effectiveness and side effects of two chemotherapy regimens, paclitaxel and carboplatin (PC), against bleomycin, etoposide, and cisplatin (BEP) in treating newly diagnosed or recurrent ovarian sex cord-stromal tumors (SCST).
- In a phase II trial involving 63 patients, the analysis showed that PC did not meet the criteria for being as effective as BEP, with a median progression-free survival of 27.7 months for PC compared to 19.7 months for BEP.
- Although PC had fewer serious adverse events (77% vs. 90%), the study concluded that it failed to demonstrate non-inferiority to BE